|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||89.02 - 90.62|
|52-week range||76.45 - 106.66|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||17.58|
|Earnings date||03 Feb 2023|
|Forward dividend & yield||3.33 (3.71%)|
|Ex-dividend date||06 May 2022|
|1y target est||102.70|
(Bloomberg) -- Haleon Plc, the consumer health business spun out from British pharmaceutical producer GSK Plc, is in the early stages of studying large potential deals to bulk up its brand portfolio, people with knowledge of the matter said. Most Read from BloombergSony Slashes PlayStation VR2 Headset Output After Pre-Orders DisappointTrump Sues Journalist Bob Woodward for Releasing Interview RecordingsWall Street Is Losing Out to Amateur Buyers in the Housing SlumpBrexit Is Costing the UK £100
Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.